Reported 2 days ago
Berenberg Bank has reaffirmed its Hold rating on Novartis AG (NYSE:NVS), setting a price target of CHF89.00. This follows the company's announcement of significant improvements in hemoglobin levels in adult PNH patients during a Phase IIIB study of the treatment Fabhalta. While Novartis is considered one of the best drug stocks to buy, the report suggests that some AI stocks may present more attractive investment opportunities.
Source: YAHOO